°øÁö»çÇ×

HOME > ÇÐȸ¼Ò°³   >   °øÁö»çÇ×

¸¸¼º°ñ¼öÁõ½ÄÁúȯ ¿¬±¸È¸ ½ÉÆ÷Áö¿ò °³ÃÖ ¾È³»
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
÷ºÎÆÄÀÏ
CMPDCC-2.jpg (Down : 714)
ÀÛ¼ºÀÏ
2007-11-19
Á¶È¸
6738
´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼öÁõ½ÄÁúȯ ¿¬±¸È¸ ½ÉÆ÷Áö¿òÀÌ ¾Æ·¡¿Í °°ÀÌ °³ÃÖµÇ´Ï ¸¹Àº °ü½É°ú Âü¼® ºÎŹµå¸³´Ï´Ù.

»çÀüµî·ÏÀº 11¿ù 21ÀÏ(¼ö)±îÁö µî·ÏÇÏ¿© ÁÖ½Ã±æ ºÎŹµå¸®¸ç, ±âŸ ÀÚ¼¼ÇÑ ³»¿ëÀº ÷ºÎÈ­ÀÏÀ» ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.


= ¾Æ·¡ =


ÁÖÁ¦ : ¸¸¼º°ñ¼öÁõ½ÄÁúȯÀÇ Áø´Ü°ú Ä¡·áÁöħ

ÀϽà : 2007³â 11¿ù 24ÀÏ(Åä) 12:30~17:30

Àå¼Ò : ÇѸ²´ëÇб³¼º½Éº´¿ø(ÆòÃÌ) Á¦2º°°ü 5Ãþ Àϼ۹®È­È¦(¾àµµ ÷ºÎÈ­ÀÏ ÂüÁ¶)

¿¬¼öÆòÁ¡ : ´ëÇÑÀÇ»çÇùȸ 3ÆòÁ¡

»çÀüµî·Ï : ´ëÇÑÇ÷¾×ÇÐȸ »ç¹«½Ç(hematology@kams.or.kr)

¸¶°¨ÀÏ : 2007³â 11¿ù 21ÀÏ(¼ö)±îÁö hematology@kams.or.kr

¹®ÀÇó : ¢Ï 02) 516-6581 FAX 02) 516-6582

Âü°¡ºñ ¹× ÁÖÂ÷ºñ : ¹«·á


* ½ÉÆ÷Áö¿ò ½ÃÀÛÀü¿¡ °£´ÜÇÑ Á¡½É ¹× ´Ù°ú(»÷µåÀ§Ä¡, ±è¹ä, Ä¿ÇÇ µî)°¡ ÁغñµÇ¾î ÀÖ½À´Ï´Ù.



ÇÁ·Î±×·¥


1ºÎ : ÁÂÀå Á¶ÇöÂù(ÇѸ²ÀÇ´ë)

13:10 - 13:40 Evolution of disease entities and diagnostic criteria of CMPD: From WHO 2001 to WHAT?
±èÈñÁø(¼º±Õ°üÀÇ´ë)

13:45 - 14:15 JAK2 V617F À¯ÀüÀÚ µ¹¿¬º¯ÀÌ °Ë»ç¹æ¹ýÀÇ ºñ±³
ÁöÇö¼÷(¿ï»êÀÇ´ë)

14:20 - 14:50 ¸¸¼º°ñ¼öÁõ½ÄÁúȯÀÇ ±¹³» ¿ªÇÐ ¹× µî·Ï»ç¾÷ÀÇ ÇöȲ
¹æ¼ö¹Ì(¼­¿ïÀÇ´ë)


2ºÎ : ÁÂÀå ±èö¼ö(ÀÎÇÏÀÇ´ë)

15:10 - 15;35 Áø¼ºÀûÇ÷±¸Áõ´ÙÁõÀÇ Ä¡·áÁöħ
¿øÁ¾È£(¼øõÇâÀÇ´ë)

15:40 - 16:05 Áø¼º°íÇ÷¼ÒÆÇÁõÀÇ Ä¡·áÁöħ
±èºÀ¼®(¼­¿ïº¸Èƺ´¿ø)

16:10 - 16:40 Risk and management of complications in patients with CMPD
Á¤Ã¶¿ø(¼º±Õ°üÀÇ´ë)

16:45 - 17:15 Treatment of HES in the era of target therapy
±èÈ¿Á¤(ÇѸ²ÀÇ´ë)